journal article·2021-09-01

Tetrahedral Framework Nucleic Acids Ameliorate Insulin Resistance in Type 2 Diabetes Mellitus via the PI3K/Akt Pathway

Yanjing Li, Yuanlin Tang, Sirong Shi, Shaojingya Gao, Yun Wang, Dexuan Xiao, Tianyu Chen, Qing He, Junjiang Zhang, Yunfeng Lin

ACS Applied Materials & Interfaces· Volume 13· Issue 34
Publisher page

Abstract

Insulin resistance (IR) is one of the essential conditions in the development of type 2 diabetes mellitus (T2DM). IR occurs in hepatic cells when the insulin receptor substrate-1 (IRS-1)/phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway is downregulated; thus, activating this pathway can significantly improve insulin sensitivity and ameliorate T2DM. Tetrahedral framework nucleic acids (tFNAs), a DNA nanomaterial, are synthesized from four single-stranded DNA molecules. tFNAs possess excellent biocompatibility and good water solubility and stability. tFNAs can promote cell proliferation, cell autophagy, wound healing, and nerve regeneration by activating the PI3K/Akt pathway. Herein, we explore the effects and underlying mechanisms of tFNAs on IR. The results displayed that tFNAs could increase glucose uptake and ameliorate IR by activating the IRS-1/PI3K/Akt pathway in glucosamine (GlcN)-stimulated HepG2 cells. By employing a PI3K inhibitor, we confirmed that tFNAs reduce IR through the PI3K/Akt pathway. Moreover, tFNAs can promote hepatic cell proliferation and inhibit GlcN-induced cell apoptosis. In a T2DM mouse model, tFNAs reduce blood glucose levels and ameliorate hepatic IR via the PI3K/Akt pathway. Taken together, tFNAs can improve hepatic IR and alleviate T2DM through the PI3K/Akt pathway, making contribution to the potential application of tFNAs in T2DM.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · MicroRNA in disease regulation · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, P. R. China

Department of Prosthodontics, Tianjin Medical University School of Stomatology, Tianjin 300070, P. R. China

West China Medical Center, Sichuan University, Chengdu 610041, P. R. China

Department of Oral and Maxillofacial Surgery, Hospital of Stomatology, Southwest Medical University, Luzhou 646000, P. R. China

College of Biomedical Engineering, Sichuan University, Chengdu 610041, P. R. China

Funding

Sichuan University · Ministry of Science and Technology of the People's Republic of China · National Natural Science Foundation of China

References (67)

Show source-provided references
1. 10.1038/s41574-018-0083-410.1038/s41574-018-0083-4 ↗
2. 10.1155/2015/18164310.1155/2015/181643 ↗
3. 10.1016/s0140-6736(76)91768-210.1016/s0140-6736(76)91768-2 ↗
4. 10.1016/j.tem.2017.03.00310.1016/j.tem.2017.03.003 ↗
5. 10.1210/er.2019-0003410.1210/er.2019-00034 ↗
6. 10.1152/physrev.00063.201710.1152/physrev.00063.2017 ↗
7. 10.1126/science.109670610.1126/science.1096706 ↗
8. 10.1038/nrm.2017.8910.1038/nrm.2017.89 ↗
9. 10.1038/nrm183710.1038/nrm1837 ↗
10. 10.1038/nrendo.2017.8010.1038/nrendo.2017.80 ↗
11. 10.1016/j.cmet.2008.05.00710.1016/j.cmet.2008.05.007 ↗
12. 10.2165/00002018-199920060-0000310.2165/00002018-199920060-00003 ↗
13. 10.1111/jog.1295010.1111/jog.12950 ↗
14. 10.1016/j.foodchem.2020.12751310.1016/j.foodchem.2020.127513 ↗
15. 10.1016/j.ejphar.2019.04.00510.1016/j.ejphar.2019.04.005 ↗
16. 10.1016/j.biopha.2017.03.04710.1016/j.biopha.2017.03.047 ↗
17. 10.1002/adma.20210094910.1002/adma.202100949 ↗
18. 10.1016/j.nantod.2021.10121110.1016/j.nantod.2021.101211 ↗
19. 10.1002/adfm.20210515210.1002/adfm.202105152 ↗
20. 10.1002/adfm.20200734210.1002/adfm.202007342 ↗
21. 10.1186/s13287-017-0648-510.1186/s13287-017-0648-5 ↗
22. 10.1016/j.mattod.2018.08.00210.1016/j.mattod.2018.08.002 ↗
23. 10.1038/s41596-020-0355-z10.1038/s41596-020-0355-z ↗
24. 10.1021/acsami.6b0378610.1021/acsami.6b03786 ↗
25. 10.1021/acsami.6b0652810.1021/acsami.6b06528 ↗
26. 10.1007/s40820-021-00614-610.1007/s40820-021-00614-6 ↗
27. 10.1021/acs.nanolett.1c0113110.1021/acs.nanolett.1c01131 ↗
28. 10.1016/j.bioactmat.2020.12.02710.1016/j.bioactmat.2020.12.027 ↗
29. 10.1016/j.cej.2020.12742610.1016/j.cej.2020.127426 ↗
30. 10.1016/j.bioactmat.2020.12.02710.1016/j.bioactmat.2020.12.027 ↗
31. 10.1021/acs.nanolett.0c0052910.1021/acs.nanolett.0c00529 ↗
32. 10.1007/s40820-020-0409-310.1007/s40820-020-0409-3 ↗
33. 10.1038/s41413-019-0077-410.1038/s41413-019-0077-4 ↗
34. 10.1016/j.apmt.2021.10109810.1016/j.apmt.2021.101098 ↗
35. 10.1039/c7cc09397g10.1039/c7cc09397g ↗
36. 10.1039/c9nr07171g10.1039/c9nr07171g ↗
37. 10.1021/acsami.0c0087410.1021/acsami.0c00874 ↗
38. 10.1021/acsami.9b1030810.1021/acsami.9b10308 ↗
39. 10.2337/diabetes.48.8.156210.2337/diabetes.48.8.1562 ↗
40. 10.7150/thno.4605310.7150/thno.46053 ↗
41. 10.1016/j.joca.2011.01.00710.1016/j.joca.2011.01.007 ↗
42. 10.1038/nature0463410.1038/nature04634 ↗
43. 10.1172/jci12084310.1172/jci120843 ↗
44. 10.1016/j.cmet.2008.06.00610.1016/j.cmet.2008.06.006 ↗
45. 10.1172/jci2573510.1172/jci25735 ↗
46. 10.1101/cshperspect.a00919110.1101/cshperspect.a009191 ↗
47. 10.1172/jci765610.1172/jci7656 ↗
48. 10.1016/j.lfs.2018.12.01510.1016/j.lfs.2018.12.015 ↗
49. 10.2337/diabetes.52.4.93510.2337/diabetes.52.4.935 ↗
50. 10.1038/s41392-020-0173-310.1038/s41392-020-0173-3 ↗
51. 10.1016/j.pharmthera.2015.08.00410.1016/j.pharmthera.2015.08.004 ↗
52. 10.3390/molecules2207118010.3390/molecules22071180 ↗
53. 10.23736/S0031-0808.18.03455-910.23736/S0031-0808.18.03455-9 ↗
54. 10.2337/db11-114110.2337/db11-1141 ↗
55. 10.1021/acsnano.7b0764310.1021/acsnano.7b07643 ↗
56. 10.1021/acsnano.9b0205010.1021/acsnano.9b02050 ↗
57. 10.2147/IJN.S6787110.2147/IJN.S67871 ↗
58. 10.1002/adma.20200370810.1002/adma.202003708 ↗
59. 10.1016/j.colsurfb.2020.11105110.1016/j.colsurfb.2020.111051 ↗
60. 10.1016/j.jhep.2020.11.03010.1016/j.jhep.2020.11.030 ↗
61. 10.1016/j.cmet.2007.05.00510.1016/j.cmet.2007.05.005 ↗
62. 10.1002/hep.2694510.1002/hep.26945 ↗
63. 10.1038/s41467-020-19668-y10.1038/s41467-020-19668-y ↗
64. 10.1016/j.amjmed.2006.01.00910.1016/j.amjmed.2006.01.009 ↗
65. 10.1002/adfm.20210414110.1002/adfm.202104141 ↗
66. 10.1002/adfm.20210143510.1002/adfm.202101435 ↗
67. 10.1016/j.cej.2020.12634410.1016/j.cej.2020.126344 ↗